A prospective, multicenter, randomized, controlled, open-label, blinded endpoint trial to evaluate the safety and efficacy of intravenous administration of tirofiban for preventing early neurological deterioration after intravenous thrombolysis in patients with acute ischemic stroke.
Age ≥18 years old;
Acute ischemic stroke treated with intravenous thrombolysis with alteplase or tenecteplase within 4.5 hours of onset or time last known well and can receive the study drug treatment within 3 hours of initiating intravenous thrombolysis.
Residual NIHSS score ≥ 5 points at randomization (at least 1 hour after intravenous thrombolytic therapy).
Post-thrombolysis imaging shows that the offending artery is consistent with moderate or severe intracranial atherosclerotic stenosis (within 50%~99%)
Intracranial hemorrhage confirmed by imaging post-thrombolysis.
Stroke caused by other determined causes, including moyamoya disease, artery dissection, arteritis, etc.
Scheduled for or received endovascular treatment after onset.
Definite or suspected cardioembolic stroke.
Capital Medical University
Lead sponsor
Xuanwu Hospital, Beijing
Sponsor institution